Minister of Trade, Industry and Competition, Parks Tau, with the Director-General of the Department of Science, Technology and Innovation, Dr Mlungisi Cele, and Biovac CEO, Dr Morena Makhoana, at the Biovac Pharma facility in Cape Town.
South Africa is strengthening its position as a continental leader in vaccine manufacturing following the expansion of the Biovac vaccine production facility in Cape Town, a project the government says will boost health security, industrialisation and economic growth across Africa.
Biovac is a South African-based biopharmaceutical company established in 2003 in partnership with government to build local vaccine manufacturing capability. The company plays a strategic role in strengthening South Africa and Africa’s health security through the production and supply of vaccines.
Speaking at the soil-turning ceremony for the facility expansion on Monday, Minister of Trade, Industry and Competition (the dtic) Parks Tau said the investment signals Africa’s growing role in global healthcare manufacturing.
The visit formed part of the dtic’s stakeholder engagement programme ahead of the 2026/27 Budget Vote and highlighted government-backed industrialisation and localisation initiatives in priority sectors.
